Holocene Advisors, LP Uni Qure N.V. Call Options Transaction History

Holocene Advisors, LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $4.53 Million - $6.7 Million	-311,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $580,888 - $1.03 Million	28,700 Added 10.14%	311,600 $6.46 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $1.12 Million - $1.64 Million	42,900 Added 17.88%	282,900 $9.06 Million
Q1 2021 May 17, 2021	SELL	$29.24 - $42.03 $1.39 Million - $2 Million	-47,500 Reduced 16.52%	240,000 $8.09 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $11.5 Million - $21.3 Million	287,500 New	287,500 $13.6 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.